NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells $4,095,234.00 in Stock

NewAmsterdam Pharma (NASDAQ:NAMS) insider Johannes Jacob Piete Kastelein sold 190,476 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, March 26th. The stock was sold at an average price of $21.50, for a total value of $4,095,234.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

NewAmsterdam Pharma Trading Down 0.1 %

NewAmsterdam Pharma stock opened at $22.70 on Thursday. NewAmsterdam Pharma has a 1-year low of $5.63 and a 1-year high of $26.35. The firm has a 50-day moving average of $21.52 and a 200-day moving average of $14.04.

Analyst Ratings Changes

NAMS has been the topic of several recent analyst reports. Royal Bank of Canada increased their target price on shares of NewAmsterdam Pharma from $25.00 to $31.00 and gave the stock an “outperform” rating in a research note on Thursday, February 29th. Guggenheim began coverage on NewAmsterdam Pharma in a report on Thursday, January 18th. They issued a “buy” rating and a $30.00 price objective for the company. Piper Sandler began coverage on NewAmsterdam Pharma in a report on Tuesday, January 16th. They set an “overweight” rating and a $37.00 price objective on the stock. Finally, Scotiabank started coverage on NewAmsterdam Pharma in a research note on Thursday, March 14th. They issued a “sector outperform” rating and a $35.00 target price for the company. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $31.00.

Institutional Trading of NewAmsterdam Pharma

Several hedge funds have recently bought and sold shares of the stock. Fcpm Iii Services B.V. purchased a new position in shares of NewAmsterdam Pharma in the fourth quarter worth $132,157,000. Goldman Sachs Group Inc. acquired a new stake in shares of NewAmsterdam Pharma in the fourth quarter valued at about $15,463,000. Opaleye Management Inc. purchased a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth about $2,964,000. Parkman Healthcare Partners LLC lifted its position in NewAmsterdam Pharma by 20.8% during the fourth quarter. Parkman Healthcare Partners LLC now owns 300,750 shares of the company’s stock valued at $3,359,000 after buying an additional 51,726 shares in the last quarter. Finally, Royal Bank of Canada increased its stake in NewAmsterdam Pharma by 987.5% during the fourth quarter. Royal Bank of Canada now owns 10,875 shares of the company’s stock valued at $121,000 after purchasing an additional 9,875 shares during the last quarter. Hedge funds and other institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE).